Ensysce Biosciences, Inc. (ENSC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 3M 6M 9M Q3 '21: 2.3M Q4 '21: 3.5M Q1 '22: 3.9M Q2 '22: 3.6M Q3 '22: 2.7M Q4 '22: 2.5M Q1 '23: 2.7M Q2 '23: 3M Q3 '23: 3.1M Q4 '23: 2.2M Q1 '24: 1.7M Q2 '24: 1.4M Q3 '24: 4.4M Q4 '24: 5.2M Q1 '25: 6.2M Q2 '25: 7.4M Q3 '25: 4.5M Q4 '25: 5.1M Q1 '26: 4.7M Q2 '26: 4.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -18.9M Q4 '21: -19.8M Q1 '22: -24.1M Q2 '22: -30.8M Q3 '22: -20M Q4 '22: -24.2M Q1 '23: -22M Q2 '23: -17.2M Q3 '23: -13.8M Q4 '23: -10.7M Q1 '24: -10M Q2 '24: -9.7M Q3 '24: -6.3M Q4 '24: -6.7M Q1 '25: -6.9M Q2 '25: -6.6M Q3 '25: -11M Q4 '25: -10.2M Q1 '26: -11.8M Q2 '26: -12.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -15.3M Q4 '21: -29.8M Q1 '22: -29.1M Q2 '22: -36.1M Q3 '22: -28.8M Q4 '22: -24.2M Q1 '23: -25.4M Q2 '23: -19.8M Q3 '23: -12.6M Q4 '23: -10.6M Q1 '24: -11.6M Q2 '24: -11.3M Q3 '24: -7.9M Q4 '24: -8M Q1 '25: -6.8M Q2 '25: -6.6M Q3 '25: -11M Q4 '25: -10.2M Q1 '26: -11.8M Q2 '26: -12.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q3 '21: -5M Q4 '21: -8.2M Q1 '22: -11.2M Q2 '22: -15.5M Q3 '22: -18.4M Q4 '22: -17.9M Q1 '23: -18.1M Q2 '23: -16.7M Q3 '23: -12.3M Q4 '23: -10.8M Q1 '24: -10.6M Q2 '24: -9.8M Q3 '24: -8.5M Q4 '24: -7.5M Q1 '25: -5.8M Q2 '25: -6.2M Q3 '25: -7M Q4 '25: -7.8M Q1 '26: -9.6M Q2 '26: -8.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 10M 20M 30M Q3 '20: 16.8M Q1 '21: 15.8M Q2 '21: 16.1M Q3 '21: 24.3M Q1 '22: 27.3M Q2 '22: 141.6K Q3 '22: 160.7K Q1 '23: 1.1M Q2 '23: 2.3M Q3 '23: 3.1M Q1 '24: 379.6K Q2 '24: 587.8K Q3 '24: 659.4K Q1 '25: 1.4M Q2 '25: 2.2M Q3 '25: 2.9M Q1 '26: 6.8M Q2 '26: 13M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-150.00 -100.00 -50.00 0.00 50.00 100.00 150.00 Q3 '20: -0.17 Q4 '20: 0.00 Q1 '21: -0.55 Q2 '21: -0.57 Q3 '21: -1.37 Q4 '21: -1.50 Q1 '23: -118.67 Q2 '23: -63.16 Q3 '23: -2.45 Q4 '23: -71.01 Q1 '24: -77.14 Q2 '24: -79.51 Q3 '24: -77.64 Q4 '24: -13.49 Q1 '25: -6.67 Q2 '25: -4.11 Q3 '25: -6.40 Q4 '25: -4.03 Q1 '26: -3.16 Q2 '26: -2.57 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.